Loss of prostaglandin D2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma

Cathy A. Payne, Sanaz Maleki, Marinella Messina, Maree G. O’Sullivan, Glenn Stone, Nathan R. Hall, Jonathon Parkinson, Helen Wheeler, Raymond Cook, Michael T. Biggs,

Molecular Cancer Therapeutics · 2008 · 27 citations · 36 references

DOIFull text

Open access

Concepts

Abstract

Reduction in the mRNA and protein expression of lipocalin-like prostaglandin D(2) (PGD(2)) synthase (PGDS), the main arachidonic acid metabolite produced in neurons and glial cells of the central nervous system, is a significant biological event involved in the malignant progression of astrocytomas and is predictive of poor survival. In vitro, the addition of the main PGDS metabolite, PGD(2), to A172 glioblastoma cells devoid of PGDS resulted in antiproliferative activity and cell death. In vitro PGD(2) substitution also enhanced the efficacy of cyclo-oxygenase-2 inhibitors. This finding has exciting implications for early interventional efforts for the grade 2 and 3 astrocytomas.

References

36